脂肪肝
酒精性肝病
肝硬化
脂肪变性
疾病
肝病
生物信息学
医学
脂质代谢
胰岛素抵抗
炎症
代谢综合征
脂毒性
生物
免疫学
胰岛素
糖尿病
内科学
内分泌学
作者
Ashwani K. Singal,Vijay H. Shah,Harmeet Malhi
出处
期刊:Hepatology
[Wiley]
日期:2023-03-21
卷期号:80 (1): 223-237
被引量:4
标识
DOI:10.1097/hep.0000000000000381
摘要
Alcohol-associated liver disease due to harmful alcohol use and NAFLD associated with metabolic syndrome are the 2 most common liver diseases worldwide. Control of respective risk factors is the cornerstone in the long-term management of these diseases. Furthermore, there are no effective therapies. Both diseases are characterized by metabolic derangements; thus, the focus of this review was to broaden our understanding of metabolic targets investigated in NAFLD, and how these can be applied to alcohol-associated liver disease. Conserved pathogenic pathways such as dysregulated lipid metabolism, cell death pathways including apoptosis and activation of innate immune cells, and stellate cells mediate both alcohol and NAFLDs, resulting in histological abnormalities of steatosis, inflammation, fibrosis, and cirrhosis. However, pathways such as gut microbiome changes, glucose metabolism and insulin resistance, inflammatory signaling, and microRNA abnormalities are distinct in these 2 diseases. In this review article, we describe conserved and distinct pathogenic pathways highlighting therapeutic targets that may be of potential in both diseases and those that are unique to each disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI